Tempest to Present at the Jefferies Healthcare Conference
Tempest Therapeutics (Nasdaq: TPST) announced its participation at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tempest Therapeutics (Nasdaq: TPST) announced its participation at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 a.m. ET. The company, focused on innovative oncology therapeutics, is advancing clinical programs TPST-1120 and TPST-1495 that target tumors through both targeted and immune-mediated mechanisms. TPST-1120 is undergoing a Phase 1b/2 study in collaboration with Roche for treating advanced hepatocellular carcinoma. For access to the presentation, visit Tempest's investor section online.
Details
News Market Reaction – TPST
The recorded move for TPST in the trading session of this news was +4.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 a.m. ET.
To access the live or archived recording of the company presentation, please visit the investor section of the Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through clinical trials designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffmann La Roche, TPST-1120 is also advancing in a randomized, global, Phase 1b/2 clinical study in combination with the standard-of-care regimen of atezolizumab and bevacizumab in the first-line treatment of patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor Contact:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@tempesttx.com
____________________
1 If approved
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.